Back to Results
First PageMeta Content
Pharmacology / Azacitidine / lactams / Chemistry / Decitabine / Hypomethylating agent / DNA methyltransferase / Nucleosides / Triazines / Medicine


First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous hypomethylating agent, in 102 patients with Intermediate or High Risk MDS or CMML On Behalf of the SGI-110 Investigative Team Guillerm
Add to Reading List

Open Document

File Size: 362,78 KB

Share Result on Facebook
UPDATE